Evidence map›Paper›PMID 31246963›Full record

SynthesisPloS one2019

Systematic review of the performance and clinical utility of point of care HIV-1 RNA testing for diagnosis and care.

Clara A Agutu, Caroline J Ngetsa, Matt A Price, Tobias F Rinke de Wit, Gloria Omosa-Manyonyi, Eduard J Sanders, Susan M Graham

Registry-linked trialOpen access · goldAbstract readSystematic Review
In one paragraph

Synthesis in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04793750 (Ending the HIV Epidemic Through Point-of-Care Technologies), which is not on this map. Cited by 31 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 5 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04793750 nacompletednot on this mapstarted 2021, after this paper: background citation

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC): Performance Evaluation of Novel POC HIV Tests in Baltimore

TypeinterventionalSponsorJohns Hopkins UniversityRan2021 to 2025Enrolled224ConditionsHIV Infections, SyphilisArmsCepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 5 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. A Randomized Trial of Point-of-Care Early Infant Human Immunodeficiency Virus (HIV) Diagnosis in Zambia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Clara A AgutuKenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.ORCID 0000-0003-1053-4463
Caroline J NgetsaKenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
Matt A PriceInternational AIDS Vaccine Initiative (IAVI), Department of Medical Affairs, New York, New York, United States of America.
Tobias F Rinke de WitDepartment of Global Health, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
Gloria Omosa-ManyonyiSchool of Medicine, College of Health Sciences, University of Nairobi, Nairobi, Kenya.
Eduard J SandersKenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
Susan M GrahamKenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.ORCID 0000-0001-7847-8686
Kenya Medical Research Institute · KEInternational AIDS Vaccine Initiative · USUniversity of Amsterdam · NLUniversity of Nairobi · KEUniversity of Washington · US

Funding

Int'l Traineeships in AIDS Prevention Studies (ITAPS)R25MH064712 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LINDAN, CHRISTINA P · 2002 to 2018
$3.4M
Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmissionR01AI124968 · NIAID · UNIVERSITY OF WASHINGTON · PI GRAHAM, SUSAN MARIE, SANDERS, EDUARD · 2016 to 2019
$2.3M
International Traineeships in AIDS Prevention Studies (ITAPS)R25MH123256 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHRISTINA P LINDAN · 2020 to 2026
$1.8M
NIAID NIH HHS R01 AI124968NIMH NIH HHS R25 MH064712NIMH NIH HHS R25 MH123256Wellcome TrustWellcome Trust 107752/Z/15/Z
6 · The paper itself

Abstract

backgroundPoint of-care (POC) HIV-1 RNA tests which are accurate and easy to use with limited infrastructure are needed in resource-limited settings (RLS). We systematically reviewed evidence of POC test performance compared to laboratory-based HIV-1 RNA assays and the potential utility of these tests for diagnosis and care in RLS.

methodsStudies published up to July 2018 were identified by a search of PUBMED, EMBASE, Web of Science, CINAHL and Cochrane Central Register of Controlled Trials. Studies evaluating the use of POC HIV-1 RNA testing for early infant diagnosis (EID), acute HIV infection (AHI) diagnosis, or viral load monitoring (VL), compared to centralized testing, were included. Separate search strategies were used for each testing objective.

results197 abstracts were screened and 34 full-text articles were assessed, of which 32 met inclusion criteria. Thirty studies evaluated performance and diagnostic accuracy of POC tests compared to standard reference tests. Two of the thirty and two additional studies with no comparative testing reported on clinical utility of POC results. Five different POC tests (Cepheid GeneXpert HIV-1 Quantitative and Qualitative assays, Alere q HIV-1/2 Detect, SAMBA, Liat HIV Quant and Aptima HIV-1 Quant) were used in 21 studies of VL, 11 of EID and 2 of AHI. POC tests were easy to use, had rapid turnaround times, and comparable accuracy and precision to reference technologies. Sensitivity and specificity were high for EID and AHI but lower for VL. For VL, lower sensitivity was reported for whole blood and dried blood spots compared to plasma samples. Reported error rates for Cepheid GeneXpert Qual (2.0%-5.0%), GeneXpert Quant (2.5%-17.0%) and Alere q HIV-1/2 Detect (3.1%-11.0%) were higher than in WHO prequalification reports. Most errors resolved with retesting; however, inadequate sample volumes often precluded repeat testing. Only two studies used POC results for clinical management, one for EID and another for VL. POC EID resulted in shorter time-to-result, rapid ART initiation, and better retention in care compared to centralised testing.

conclusionsPerformance of POC HIV-1 RNA tests is comparable to reference assays, and have potential to improve patient outcomes. Additional studies on implementation in limited-resources settings are needed.

Indexed as

Point-of-Care TestingRNA, ViralAge FactorsHIV-1HIV InfectionsHumansPoint-of-Care SystemsPolymerase Chain ReactionReproducibility of ResultsSensitivity and SpecificityViral LoadRNA, Viral

Identifiers

PMID31246963
PMCPMC6597060
OpenAlexW2954563756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.